X4 Pharmaceuticals Reports First Quarter Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
X4 Pharmaceuticals (XFOR) Misses Q1 EPS by 44c
May 6, 2021 8:25 AM EDTX4 Pharmaceuticals (NASDAQ: XFOR) reported Q1 EPS of ($1.30), $0.44 worse than the analyst estimate of ($0.86).
We are excited by the strong progress we have achieved to date in 2021 in the development of mavorixafor across multiple rare disease indications, said Paula Ragan, Ph.D., President and Chief... More
